Quarterly Financial Information (Unaudited)

12 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information (Unaudited)

The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.


	Three Months Ended
	March 31, 2020		June 30, 2020		September 30, 2020		December 31, 2020 (1)
Total revenues	$	29,838	$	30,424	$	23,583	$	19,333
Operating loss	(16,600)		(11,830)		(23,006)		(35,167)
Loss from continuing operations	(20,846)		(15,709)		(27,536)		(39,682)
Net loss attributable to Precigen	(55,998)		(43,354)		(29,508)		(41,661)
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(0.13)	$	(0.10)	$	(0.17)	$	(0.22)
Net loss attributable to Precigen per share, basic and diluted	$	(0.35)	$	(0.26)	$	(0.18)	$	(0.23)

(1)During the fourth quarter of 2020, the Company recorded a loss on settlement agreement related to Harvest (Note 17).


	Three Months Ended
	March 31, 2019		June 30, 2019		September 30, 2019		December 31, 2019 (1)
Total revenues	$	22,585	$	32,836	$	18,299	$	17,002
Operating loss	(41,855)		(21,508)		(34,702)		(68,724)
Loss from continuing operations	(44,539)		(22,440)		(39,119)		(64,236)
Net loss attributable to Precigen	(60,709)		(38,766)		(53,634)		(169,215)
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(0.28)	$	(0.14)	$	(0.25)	$	(0.41)
Net loss attributable to Precigen per share, basic and diluted	$	(0.40)	$	(0.25)	$	(0.35)	$	(1.09)

(1)During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).